Breast Cancer in Patients 80 Years-Old and Older.
Breast cancer
chemotherapy
geriatric
octogenarians
radiotherapy
retrospective
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
27
03
2020
accepted:
24
04
2020
entrez:
14
7
2020
pubmed:
14
7
2020
medline:
14
7
2020
Statut:
epublish
Résumé
Breast cancer is the most common cancer in women and one in ten patients affected are over age 80. However, this age group is mostly excluded from clinical trials and data to inform their care is sparse. Medical records of all patients aged 80 years-old and older diagnosed and treated for breast cancer in a single center over a six-year period were retrospectively reviewed. A cohort of patients aged 65 to 75 treated for breast cancer at the same center during the same period was also reviewed for comparison. Patients in the 80 and over age group were commonly diagnosed with stage II or III disease (39.2%) compared to younger patients who were diagnosed more commonly (61.6%) with stage I disease. Sub-types of breast cancer had a similar representation in the two groups. Hormonal therapy was used equally in the two groups, but significantly fewer patients in the 80 and over age group had radiation therapy and chemotherapy as part of their treatment. Despite these differences, recurrence rates were not significantly different between the two groups. Individualized treatments taking into consideration the patient's general status, comorbidities and life expectancy are feasible in the older breast cancer population and result in outcomes similar to those of younger patients in the short and intermediate terms.
Identifiants
pubmed: 32656522
doi: 10.5152/ejbh.2020.5659
pii: ejbh-16-3-208
pmc: PMC7337909
doi:
Types de publication
Journal Article
Langues
eng
Pagination
208-212Informations de copyright
Copyright © 2020 Turkish Federation of Breast Diseases Associations.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no conflicts of interest to declare.
Références
Biomed J. 2019 Feb;42(1):66-74
pubmed: 30987708
Clin Breast Cancer. 2019 Jun;19(3):157-164
pubmed: 30819504
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
Cancer Med. 2018 May 15;:
pubmed: 29761914
Lancet. 2020 Mar 7;395(10226):817-827
pubmed: 32145796
J Chemother. 2018 Sep;30(5):266-279
pubmed: 29943680
Anticancer Res. 2016 Nov;36(11):5607-5622
pubmed: 27793883
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
J Oncol Pract. 2016 Feb;12(2):123-32
pubmed: 26869650
J Oncol Pract. 2016 Feb;12(2):133-4
pubmed: 26869651
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685
Breast Cancer Res Treat. 2011 Aug;129(1):229-33
pubmed: 21431871
Eur J Cancer Care (Engl). 2019 Nov;28(6):e13144
pubmed: 31429128
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Arch Intern Med. 1992 May;152(5):922-5
pubmed: 1580716
Breast. 2018 Apr;38:81-85
pubmed: 29274475
Oncologist. 2005 Sep;10(8):602-12
pubmed: 16177284
J BUON. 2013 Apr-Jun;18(2):328-34
pubmed: 23818342
Breast Care (Basel). 2019 Apr;14(2):86-92
pubmed: 31798379
Ann Surg Oncol. 2018 Jun;25(6):1495-1501
pubmed: 29427213
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
J Am Coll Surg. 2008 Jan;206(1):66-75
pubmed: 18155570
Breast J. 2012 Nov-Dec;18(6):650-1
pubmed: 23110369
Cancer J. 2017 Jul/Aug;23(4):246-253
pubmed: 28731949
JAMA. 2015 Oct 20;314(15):1599-614
pubmed: 26501536